-
公开(公告)号:US20190247500A1
公开(公告)日:2019-08-15
申请号:US16343701
申请日:2017-10-19
申请人: CITY OF HOPE
发明人: Don J. Diamond
IPC分类号: A61K39/395 , A61K35/17 , A61K39/245 , C07K16/28 , C07K14/725 , C12N5/0783 , A61P35/00 , C07K14/705 , C07K14/73
CPC分类号: A61K39/39558 , A61K35/17 , A61K39/12 , A61K39/245 , A61K39/285 , A61K2039/5256 , A61K2039/585 , A61P31/20 , A61P35/00 , C07K14/00 , C07K14/005 , C07K14/7051 , C07K14/70514 , C07K14/70517 , C07K14/70578 , C07K16/2803 , C07K2319/03 , C07K2319/33 , C12N5/0636 , C12N15/86 , C12N2710/16122 , C12N2710/16134 , C12N2710/24134 , C12N2710/24143
摘要: A method for treating a patient comprising: (a) providing a composition comprising a population of T cells expressing both a chimeric antigen receptor (CAR) and a T cell receptor specific for a cytomegalovirus (CMV) antigen; (b) administering the composition to the patient; and (c) administering to the patient a viral vector encoding: (i) CMV pp65 and (ii) a fusion protein comprising exon 4 of CMV protein IE1 (e4) and exon 5 of CMV protein IE2 (e5) either prior to or subsequent to administering the composition comprising a population of T cells to the patient is described.
-
公开(公告)号:US20190240301A1
公开(公告)日:2019-08-08
申请号:US16249616
申请日:2019-01-16
发明人: David F. Stojdl , John Cameron Bell , Brian Lichty , Jonathan Pol
IPC分类号: A61K39/00 , A61K39/12 , A61K35/766 , C12N7/00 , C12N15/86
CPC分类号: A61K39/0005 , A61K35/766 , A61K39/0011 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , A61K2039/55561 , A61K2039/572 , A61K2039/585 , C07K2319/00 , C07K2319/50 , C12N7/00 , C12N15/86 , C12N2710/10343 , C12N2710/16234 , C12N2710/20034 , C12N2740/15043 , C12N2760/20223 , C12N2760/20232 , C12N2760/20242 , C12N2760/20243 , A61K2300/00
摘要: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
-
公开(公告)号:US20190231866A1
公开(公告)日:2019-08-01
申请号:US16255987
申请日:2019-01-24
发明人: Maria Grazia PAU , Daniel John STIEH , Frank TOMAKA , Steven NIJS
CPC分类号: A61K39/21 , A61K2039/5256 , A61K2039/545 , A61K2039/55505 , A61P31/18 , C07K14/161 , C07K14/162 , C12N7/00 , C12N2710/10034 , C12N2710/10043 , C12N2710/10071 , C12N2740/16134 , C12N2740/16171 , C12N2740/16234 , C12N2740/16271
摘要: Provided are means and methods for generating safe immune responses in humans against multiple clades of human immunodeficiency virus (HIV). The observed immune responses were improved over earlier reported immune responses in clinical trials.
-
公开(公告)号:US20190209668A1
公开(公告)日:2019-07-11
申请号:US16097156
申请日:2017-04-26
发明人: Kaspars TARS
CPC分类号: A61K39/0008 , A61K39/12 , A61K39/35 , A61K2039/5256 , A61K2039/5258 , A61K2039/552 , A61P37/00 , C07K14/005 , C07K14/08 , C07K16/244 , C12N7/00 , C12N2760/00022 , C12N2760/00023 , C12N2760/00034 , C12N2760/16034 , C12N2770/14022 , C12N2770/14023
摘要: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.
-
公开(公告)号:US20190194690A1
公开(公告)日:2019-06-27
申请号:US16329098
申请日:2017-08-29
发明人: Brian Robert CHAMPION , Alice Claire Noel BROMLEY , Joshua David FREEDMAN , Kerry David FISHER , Leonard William SEYMOUR
CPC分类号: C12N15/86 , A61K35/761 , A61K38/00 , A61K39/39558 , A61K2039/505 , A61K2039/5256 , A61K2039/585 , A61K2300/00 , A61P35/00 , C07K14/521 , C07K16/2809 , C07K16/30 , C07K16/40 , C07K2317/31 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/75 , C07K2319/92 , C12N2710/10332 , C12N2710/10343 , C12N2830/60 , C12N2840/44
摘要: A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell engager (BiTE™) comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.
-
公开(公告)号:US20180311291A1
公开(公告)日:2018-11-01
申请号:US15967093
申请日:2018-04-30
IPC分类号: A61K35/761 , A61K39/00 , C12N7/00
CPC分类号: A61K35/761 , A61K39/0011 , A61K2039/5256 , C12N7/00 , C12N2710/10332 , C12N2710/10343
摘要: The present disclosure relates to a group B adenovirus comprising a sequence of formula (I):5′ITR-B1-BA-B2-BX-BB-BY-B3-3′ITR wherein: B1 is bond or comprises: E1A, E1B or E1A-E1B; BA comprises-E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.
-
公开(公告)号:US20180271971A1
公开(公告)日:2018-09-27
申请号:US15964198
申请日:2018-04-27
IPC分类号: A61K39/125 , C12N7/00 , A61K39/12 , A61K39/13 , A61K39/00
CPC分类号: A61K39/125 , A61K39/12 , A61K39/13 , A61K2039/5256 , A61K2039/5258 , A61K2039/70 , C12N7/00 , C12N2710/14043 , C12N2770/32323 , C12N2770/32334 , C12N2770/32351 , C12N2770/32371 , C12N2770/32634 , Y02A50/466
摘要: The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection.
-
公开(公告)号:US10080797B2
公开(公告)日:2018-09-25
申请号:US15244006
申请日:2016-08-23
申请人: Yongxiang Zhao
IPC分类号: A61K31/702 , A61K31/715 , A61K35/18 , A61K38/00 , A61K38/14 , A61K39/17 , C12N7/00 , C12N9/10
CPC分类号: A61K39/17 , A61K35/768 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/585 , C12N7/00 , C12N9/1051 , C12N15/86 , C12N2760/18121 , C12N2760/18132 , C12N2760/18134 , C12N2760/18143 , C12Y204/01087
摘要: Provided are an oncolytic heterologous recombinant Newcastle disease virus (NDV), preparation method and application thereof. The heterologous recombinant NDV can express alpha (1,3) galactosyltransferase (α1,3GT). The α1,3GT is the protein represented by the flowing B1) and B2): B1) the protein has an amino acid sequence of SEQ ID No.1; and B2) the protein is derived from B1) and has a function of α1,3GT obtained by substituting and/or deleting and/or adding one or more amino acid residue(s) in the amino acid sequence represented by SEQ ID No.1. The recombination NDV can be used for tumor treatment.
-
9.
公开(公告)号:US20180256706A1
公开(公告)日:2018-09-13
申请号:US15972277
申请日:2018-05-07
申请人: CEVA SANTE ANIMALE
发明人: AYUMI FUJISAWA , MAYUMI KUBOMURA , SAKIKO SAEKI , SHUJI SAITO
IPC分类号: A61K39/245 , A61K39/17 , C12N7/00
CPC分类号: A61K39/245 , A61K39/12 , A61K39/17 , A61K2039/5256 , A61K2039/552 , A61K2039/70 , C12N7/00 , C12N15/86 , C12N2710/16321 , C12N2710/16334 , C12N2710/16343 , C12N2720/10034 , C12N2760/18134
摘要: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
-
公开(公告)号:US20180243407A1
公开(公告)日:2018-08-30
申请号:US15874794
申请日:2018-01-18
发明人: William L. HEYWARD
CPC分类号: A61K39/292 , A61K31/713 , A61K39/12 , A61K39/39 , A61K39/42 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55511 , A61K2039/55561 , A61K2039/57 , A61K2039/575 , C07K16/08 , C07K16/082 , C12N7/00 , C12N15/113 , C12N15/86 , C12N2730/10134 , C12N2730/10171 , C12N2770/20033
摘要: The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis B virus in individuals in need thereof.
-
-
-
-
-
-
-
-
-